



Predictors of six-month mortality subsequent to chronic dialysis initiation among an older adult population, and development of a clinical risk prediction tool


James Wick  
University of Calgary

CAHSPR – Concurrent Session A4  
May 26, 2015



*The ICDC is funded by Alberta Innovates Health Solutions - CRIO Team Grants Program*

# Updated results



Abstract

Presentation

# Outline

- Background
- Objectives
- Methods & Cohort Formation
- Cohort Characteristics
- Predictors
- Illustration of points system
- Strengths/Limitations

# Background


- Chronic Kidney Disease
  - Reduced kidney function
  - <60% of healthy kidney (estimate glomerular filtration rate)
- End-Stage Renal Disease
  - Severely reduced function (<15%)
  - Kidney Failure

# Background

- Treatment of kidney failure
  - Dialysis Initiation
  - Renal Transplant
  - Conservative Care

# Rationale

- Older Adults (Age 65+)
  - Increasing incidence of chronic dialysis
  - Increased risk of mortality generally, and on dialysis



Survival and Functional Status of nursing home residents after dialysis initiation. From Kurella Tamura et al. 2009

# Objectives

- To determine the **predictors of six-month mortality** subsequent to chronic dialysis initiation among an older adult population
- To derive and internally validate a **clinical risk prediction tool for six-month mortality** following chronic dialysis initiation in this population.

# Identification of cohort

- Linkage of several data sources (administrative, lab)
- Adults aged  $\geq 65$  years in Alberta, Canada
- Dialysis initiation based on recording in Northern and Southern Alberta Renal Program (NARP/SARP) databases
- Study Period: May 1, 2003 to March 31, 2012
- Exclusions: prior dialysis or renal transplant



# Population

- n=2,211 Alberta residents age  $\geq 65$  years old at initiation of chronic dialysis, between May 1, 2003 – March 31, 2012

# Outcome

- Outcome of interest
  - Mortality within 6 months (182 days) of chronic dialysis initiation (as denoted in Alberta Registry)
- Follow-up end
  - Outmigration
  - Renal Transplant
  - Survival beyond 6 months

# Potential Predictors


- A total of 62 were available
- 5 categories:
  - Sociodemographic information
  - Comorbid conditions
    - Previously validated algorithms
  - Dialysis-related
  - Health system usage
  - Laboratory

# Analysis

- Criteria for inclusion in model selection
- Clinical relevance
  - Discussions with clinical experts
    - Clinical significance
    - Viable mechanism for predictor
- Statistical usefulness
  - Descriptive statistics

# Analysis

- Model derivation
  - Logistic Regression
  - Backward elimination
  - 10-fold cross validation run 50 times (500 total models)



- Combination into (reasonably) stable final model

# Model Discrimination

- Measured using C-Statistic
- Given two random individuals from study, how often is the one with a higher risk of the outcome the one who had the outcome?

# Model Calibration

- How well does the model prediction fit what's actually observed?
  - Split data by (approx.) deciles (0-10<sup>th</sup> percentile, 11-20 etc.) of risk
  - Observed proportion of deaths vs. expected proportion in each decile

# Results



# Select cohort characteristics

Characteristics		Overall ( n=2,211 ) %
<b>Age</b>	65-69	26.1
	70-74	25.2
	75-79	24.6
	80+	24.2
<b>Vascular Access</b>	Central Venous Catheter	68.2
	Arteriovenous Fistula/Graft	17.4
	Peritoneal Dialysis Catheter	14.4
<b>Baseline eGFR</b>	0-9.9	60.5
	10-14.9	19.7
	15+	19.8
<b>Proteinuria</b>	Normal	12.3
	Mild	19.3
	Heavy	56.2
	Missing	12.2
<b>Atrial Fibrillation</b>		24.6
<b>Lymphoma</b>		4.0

# Select cohort characteristics

Characteristics		Overall ( n=2,211 ) n	Died ( n=386 ) %
<b>Age</b>	Age 65-69	576	15.5
	Age 70-74	557	15.8
	Age 75-79	544	16.7
	Age 80+	534	22.1
<b>Vascular Access</b>	Central Venous Catheter	1508	22.7
	Arteriovenous Fistula/Graft	384	6.0
	Peritoneal Dialysis Catheter	319	6.6
<b>Baseline eGFR</b>	0-9.9	1331	12.3
	10-14.9	434	17.1
	15+	435	31.7
<b>Proteinuria</b>	Normal	271	29.2
	Mild	428	20.1
	Heavy	1244	12.4
	Missing	269	25.3
<b>Atrial Fibrillation</b>		544	28.5
<b>Lymphoma</b>		88	43.2

# Fig 1. Significant predictors of 6-mo mortality





Figure 1. Significant predictors of mortality within six months of chronic dialysis initiation


# Discrimination/C-Statistic



Area under ROC curve = 0.7474

$C=0.7474$   
(~74.7% of the time; "good" discrimination)

# Model Calibration



Hosmer-Lemeshow Goodness of Fit=3.85;  $p=0.87$  (well calibrated)

# Points score system

- Assigning points based on risk is more intuitive than calculating regression coefficients.
- Assign each predictor a points score based on its regression coefficient.
- If an individual has predictor  $x$ , score  $y$  points for that predictor.
  - E.g. Age 80+ is worth 2 points
- 46-point scale

# Example 1

- 82 year old
- Central-Venous Catheter
- GFR >15
- No proteinuria measurement
- Lymphoma

Category	Points	Example 1
Age 65-69.9	0	
Age 70-74.9	0	
Age 75-79.9	0	
Age 80+	2	2
Central Venous Catheter	7	7
Arteriovenous Fistula/Graft	0	
PD Catheter	1	
GFR < 10	0	
GFR 10-14	2	
GFR 15+	4	4
Missing GFR	23	
Normal Proteinuria	4	
Mild Proteinuria	2	
Heavy Proteinuria	0	
Missing Proteinuria	4	4
Atrial Fibrillation	4	
Lymphoma	7	7
<b>TOTAL</b>	<b>0 to 46</b>	<b>24</b>

# Example 2

- 67 year old
- Arteriovenous Graft
- GFR < 10
- Mild Proteinuria

Category	Points	Example 2
Age 65-69.9	0	0
Age 70-74.9	0	
Age 75-79	0	
Age 80+	2	
Central Venous Catheter	7	0
Arteriovenous Fistula/Graft	0	
PD Catheter	1	
GFR < 10	0	0
GFR 10-14	2	
GFR 15+	4	
Missing GFR	23	
Normal Proteinuria	4	2
Mild Proteinuria	2	
Heavy Proteinuria	0	
Missing Proteinuria	4	
Atrial Fibrillation	4	
Lymphoma	7	
<b>TOTAL</b>	<b>0 to 46</b>	<b>2</b>



# Points

- Example 1: 24 points = ~50-60% risk of mortality
- Example 2: 2 points = ~5% risk of mortality
- ↑ points = ↑ predicted risk of mortality

# Strengths & Limitations

- Strengths
  - Well-defined population-based cohort (minimize selection bias)
  - Covers all of Alberta
- Limitations
  - Data in this study are for Alberta patients, potentially limited generalizability to other settings
  - From administrative data, which may result in residual confounding.
  - Not externally validated, would perform worse in another population

# Acknowledgements

- MSc. Supervisors
  - Dr. Brenda Hemmelgarn
  - Dr. Tanvir Chowdhury Turin
- Additional Co-authors
  - Peter Faris
  - Jennifer MacRae
  - Robert Weaver
- MSc. Support
  - Alberta Innovates Health Solutions Graduate Fellowship



UNIVERSITY OF  
CALGARY





# Thank you



---

*The ICDC is funded by Alberta Innovates Health Solutions - CRIO Team Grants Program*